Omeros
About OmerosPipelineInvestorsNews


2017 Press Releases

E-mail Alerts Receive E-mail Alerts | RSS RSS Feeds
Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013 | 2012
DateTitle  
03/16/17Omeros Corporation Reports Fourth Quarter and Year-End 2016 Financial Results
-- Conference Call Today at 4:30 p.m. ET -- SEATTLE--(BUSINESS WIRE)--Mar. 16, 2017-- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced recent highlights and developments as well as fin... 
 Printer Friendly Version
03/10/17Omeros Corporation to Announce Fourth Quarter and Year-End 2016 Financial Results on March 16, 2017
SEATTLE--(BUSINESS WIRE)--Mar. 10, 2017-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its fourth quarter and year-end 2016 financial results for the period ended December 31, 2016, on Thursday, March 16, 2017, after the market closes. Omeros management will host a conference call and webcast that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results. Conference Call Detai... 
 Printer Friendly Version
03/02/17Omeros to Present at the Cowen and Company Annual Health Care Conference
SEATTLE--(BUSINESS WIRE)--Mar. 2, 2017-- Omeros Corporation (NASDAQ: OMER) today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the Cowen and Company 37th Annual Health Care Conference in Boston, MA next week. The presentation is scheduled for Tuesday, March 7, 2017 at 10:40 a.m. EST. The presentation will be webcast. The live and archived webcasts can be accessed on the “Events” page of th... 
 Printer Friendly Version
03/01/17Omeros Reports Additional Positive Results from OMS721 Phase 2 Trial in Patients with Stem Cell Transplant-Associated Thrombotic Microangiopathy
--Data Presented at the Recent Combined International and American Blood & Marrow Transplantation Meetings-- SEATTLE--(BUSINESS WIRE)--Mar. 1, 2017-- Omeros Corporation (NASDAQ: OMER) today announced additional positive data from the ongoing Phase 2 clinical trial evaluating OMS721 in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HCT-TMA). These data were presented at the combined annual meeting... 
 Printer Friendly Version